Description
2,3-dinor-6-keto Prostaglandin F1α-d9 (2,3-dinor-6-keto PGF1α-d9) (sodium salt) is intended for use an internal standard for the quantification of 2,3-dinor-6-keto PGF1α (sodium salt) by GC- or LC-MS. 2,3-dinor-6-keto PGF1α is the β-oxidation product of 6-keto PGF1α and the major urinary metabolite of PGI2 in humans.1,2 2,3-dinor-6-keto PGF1α makes up 23% of the recovered radioactivity in urine after administration of labeled 6-keto PGF1α and 20.5% after administration of labeled PGI2.2 In healthy human subjects, the average excreted 2,3-dinor-6-keto PGF1α level is ~100 pg/mg creatinine.3WARNING This product is not for human or veterinary use.
References
[1] G A FITZGERALD. Analysis of urinary metabolites of thromboxane and prostacyclin by negative-ion chemical-ionization gas chromatography/mass spectrometry.[J]. Advances in prostaglandin, thromboxane, and leukotriene research, 1985, 15: 87-90.
[2] B. ROSENKRANZ . Identification of the major metabolite of prostacyclin and 6-ketoprostaglandin F1α in man[J]. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1980, 619 2: Pages 207-213. DOI:
10.1016/0005-2760(80)90069-7[3] A WENNMALM. 2,3-Dinor metabolites of thromboxane A2 and prostacyclin in urine from healthy human subjects: diurnal variation and relation to 24h excretion.[J]. Clinical science, 1992, 83 4: 461-465. DOI:
10.1042/cs0830461[4] JIE YANG. Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity[J]. Nature, 2025, 640 8060: 1052-1061. DOI:
10.1038/s41586-025-08626-7[5] AI SASAKI. Determination of ω-6 and ω-3 PUFA metabolites in human urine samples using UPLC/MS/MS[J]. Analytical and Bioanalytical Chemistry, 2015, 407 6: 1625-1639. DOI:
10.1007/s00216-014-8412-5
